Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation TCT 2025

TCT 277: Characteristics and Clinical Outcomes of DanGer Shock-Like and Non–DanGer Shock-Like Patients in AMICS Treated With Impella Support: Insights from RECOVER III and NCSI Registries

Presenter: Batla Falah

October 27, 2025

Presentation TCT 2025

TCT 274: pLVAD-Supported Cardiogenic Shock in STEMI vs. NSTEMI: Does Myocardial Infarction Type Matter? Insights from RECOVER III and NCSI

Presenter: Batla Falah

October 27, 2025

Presentation TCT 2022

Best Practices in CGS: Data Driven Decision Making from the NCSI, RECOVER-IV, and CERAMICS Studies

Presenter: Katherine Kunkel

September 17, 2022

Presentation THT 2022

Leasons Learned From the National Cardiogenic Shock Initiative (NCSI)

Presenter: William O'Neill

February 02, 2022

News Daily News

SCAI SHOCK: Update Refines Cardiogenic Shock Classification

Caitlin E. Cox

January 31, 2022

News Industry News

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

May 13, 2021

News Conference News SCAI 2021

Cardiogenic Shock: Protocols, Clear Definitions Advance the Field

Caitlin E. Cox

April 30, 2021

News Daily News

New Review Urges Rethink of Cardiogenic Shock Care

Caitlin E. Cox

October 27, 2020

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

News Daily News

Multivessel PCI May Be Safe in Select Shock Patients With Impella Support

Todd Neale

April 29, 2020

News Conference News TCT 2019

NCSI Strategy for Acute MI Cardiogenic Shock Reaps Better Survival

Caitlin E. Cox

October 10, 2019

News Conference News SCAI 2019

National Cardiogenic Shock Initiative Shows Potential to Increase Survival

Yael L. Maxwell

May 23, 2019

News Daily News

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

Caitlin E. Cox

December 11, 2018

News Industry News

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

May 24, 2018

News Industry News

NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient to correct “torrential” tricuspid regurgitation (TR)

August 30, 2017

News Industry News

NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation

April 26, 2017

News Industry News

NaviGate Cardiac Structures Inc. (“NCSI”) Reports First Patient Treated for Mitral Regurgitation (“MR”)

November 22, 2015

Advertisement

TCT 277: Characteristics and Clinical Outcomes of DanGer Shock-Like and Non–DanGer Shock-Like Patients in AMICS Treated With Impella Support: Insights from RECOVER III and NCSI Registries

TCT 274: pLVAD-Supported Cardiogenic Shock in STEMI vs. NSTEMI: Does Myocardial Infarction Type Matter? Insights from RECOVER III and NCSI

Best Practices in CGS: Data Driven Decision Making from the NCSI, RECOVER-IV, and CERAMICS Studies

Leasons Learned From the National Cardiogenic Shock Initiative (NCSI)

SCAI SHOCK: Update Refines Cardiogenic Shock Classification

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

Cardiogenic Shock: Protocols, Clear Definitions Advance the Field

New Review Urges Rethink of Cardiogenic Shock Care

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

Multivessel PCI May Be Safe in Select Shock Patients With Impella Support

NCSI Strategy for Acute MI Cardiogenic Shock Reaps Better Survival

National Cardiogenic Shock Initiative Shows Potential to Increase Survival

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient to correct “torrential” tricuspid regurgitation (TR)

NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation

NaviGate Cardiac Structures Inc. (“NCSI”) Reports First Patient Treated for Mitral Regurgitation (“MR”)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content